The selection for this best of ASH article was based on the studies that were selected for presentation during the presidential symposium, the late breaking abstract session and the “best of ASH” session at the 2017 annual meeting of the American Society of Hematology (ASH). The selection is primarily targeted at clinicians and the information from these sessions was grouped into 5 chapters: studies likely to have an impact on our clinical practice on the short term, early clinical trials with promising new treatments, therapeutic advances in rare hematological diseases, new insights in mechanisms of disease and innovative applications for next generation sequencing (NGS).

(BELG J HEMATOL 2018;9(1):3–7)